Aurobindo Pharma has received tentative approval from the US Food and Drug Administration (USFDA) for its Ritonavir tablets (100 mg) used for the treatment of human immunodeficiency virus (HIV) infection. Established in 1986, the pharmaceutical firm is present in semi-synthetic penicillins and therapeutic segments such as neurosciences, anti-retrovirals, anti-diabetics, and gastroenterology.